Determining An Cheapest AZD5363 Offer

16 (95% CI, 0.00-8.31) vs 0.12 (95% CI, 0.02-0.77). Both studies documenting AZD5363 molecular weight therapeutic anticoagulation reported rates of thrombus progression. There was no difference between the pooled rate of thrombus progression between this subgroup and the subgroup of studies that did not report efficacy of anticoagulation, with ORs for thrombus progression of 0.14 (95% CI, 0.02-0.87) vs 0.34 (95% CI, 0.15-0.77). Mortality results were unchanged based on subgroup analysis. In studies reporting therapeutic anticoagulation, there appeared to be an increase in bleeding events compared with those not reporting anticoagulation, with an OR of 21.7 (95% CI, 1.1-424.7) vs 0.16 (95% CI, 0.01-2.6). From the results C646 cost of an RCT that demonstrated 6 weeks of anticoagulation was sufficient for the treatment of calf vein DVT,19 we dichotomized included studies into those that treated patients for >6 weeks or Chlormezanone generation (Fig 6). The six remaining observational studies had a mean NOS score of 5 (range, 4-7). Demonstration that the outcome of interest was not present at baseline and adequacy of follow-up were the most frequent missing items (Table II). Thrombus progression was the only outcome with enough studies to create a funnel plot for evaluation of publication bias. On visual inspection, it appears that a bias is present for studies observing a treatment effect (Fig 7). Clinicians struggle to balance the morbidity and mortality from thromboembolic complications after isolated cDVT with the risks of anticoagulation. The current study attempts a systematic appraisal of the available literature concerning comparative anticoagulation treatment for cDVT. Our findings suggest that treatment of cDVT with anticoagulation may result in a significant reduction in occurrence of PE and proximal thrombus propagation.